{"id":"dg3173","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3989911","moleculeType":"Protein","molecularWeight":"1123.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of DG3173 is not well understood, but it is believed to work by interacting with the [unknown molecular target].","oneSentence":"DG3173 is a small molecule that targets the [unknown molecular target] to exert its therapeutic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:32:31.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02217800","phase":"PHASE2","title":"The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2013-11","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT02235987","phase":"PHASE2","title":"Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2012-10","conditions":"Acromegaly","enrollment":20},{"nctId":"NCT02217826","phase":"PHASE1","title":"Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":8},{"nctId":"NCT02217488","phase":"PHASE1","title":"Single Ascending Dose Tolerability Study of DG3173","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT02217839","phase":"PHASE1","title":"Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2012-04","conditions":"Healthy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DG3173","genericName":"DG3173","companyName":"Aspireo Pharmaceuticals Limited","companyId":"aspireo-pharmaceuticals-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}